This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, B. Articles by Parker, M. I. Search for Related Content PubMed PubMed Citation Articles by Wang, B. Articles by Parker, M. I.

A Growth-Related Oncogene/CXC Chemokine Receptor 2 Autocrine Loop Contributes to Cellular Proliferation in Esophageal Cancer

Division of Medical Biochemistry, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

Requests for reprints: M. Iqbal Parker, Division of Medical Biochemistry, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, 7925 Cape Town, South Africa. Phone: 27-21-4066335; Fax: 27-21-4066061; E-mail: mparker{at}curie.uct.ac.za.

Growth-related oncogene (GRO), a member of the CXC chemokine subfamily, plays a major role in inflammation and wound healing. CXC chemokines have been found to be associated with tumorigenesis, angiogenesis, and metastasis. Although elevated expression of GRO has been reported in several human cancers, the expression and role of GRO and its receptor, CXCR2, in esophageal cancer are poorly understood. This study used real-time reverse transcription-PCR (RT-PCR) and immunohistochemical approaches to show that GRO, GROß, and CXCR2 are up-regulated in esophageal tumor tissue. Furthermore, GRO, GROß, and CXCR2 are constitutively expressed in WHCO1, an esophageal cancer cell line that was used as a model system here. GROß enhances transcription of EGR-1, via the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, which can be blocked by a specific antagonist of CXCR2 (SB 225002) or specific antibody to GROß. WHCO1 cells treated with SB 225002 exhibited a 40% reduction in cell proliferation. A stable WHCO1 GRO RNA interference (RNAi) clone displayed a 43% reduction in GRO mRNA levels as determined by real-time RT-PCR, reduced levels of GRO by fluorescence microscopy, and a 60% reduction in the levels of phosphorylated ERK1/2. A stable clone expressing GROß RNAi displayed >95% reduction in GROß mRNA levels, reduced levels of GROß by fluorescence microscopy, and an 80% reduction in the levels of phosphorylated ERK1/2. Moreover, these GRO RNAi- and GROß RNAi-expressing clones displayed a 20% and 50% decrease in cell proliferation, respectively. Our results suggest that GRO-CXCR2 and GROß-CXCR2 signaling contributes significantly to esophageal cancer cell proliferation and that this autocrine signaling pathway may be involved in esophageal tumorigenesis. (Cancer Res 2006; 66(6): 3071-7)

This article has been cited by other articles:

				A. E. Wallace, K. J. Sales, R. D. Catalano, R. A. Anderson, A. R.W. Williams, M. R. Wilson, J. Schwarze, H. Wang, A. G. Rossi, and H. N. Jabbour Prostaglandin F2{alpha}-F-Prostanoid Receptor Signaling Promotes Neutrophil Chemotaxis via Chemokine (C-X-C Motif) Ligand 1 in Endometrial Adenocarcinoma Cancer Res., July 15, 2009; 69(14): 5726 - 5733. [Abstract] [Full Text] [PDF]

				W. Yan and X. Chen Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function J. Biol. Chem., May 1, 2009; 284(18): 12178 - 12187. [Abstract] [Full Text] [PDF]

				B. Wang, L. M. Khachigian, L. Esau, M. J. Birrer, X. Zhao, M. I. Parker, and D. T. Hendricks A Key Role for Early Growth Response-1 and Nuclear Factor-{kappa}B in Mediating and Maintaining GRO/CXCR2 Proliferative Signaling in Esophageal Cancer Mol. Cancer Res., May 1, 2009; 7(5): 755 - 764. [Abstract] [Full Text] [PDF]

				V. Levina, B. M. Nolen, A. M. Marrangoni, P. Cheng, J. R. Marks, M. J. Szczepanski, M. E. Szajnik, E. Gorelik, and A. E. Lokshin Role of Eotaxin-1 Signaling in Ovarian Cancer Clin. Cancer Res., April 15, 2009; 15(8): 2647 - 2656. [Abstract] [Full Text] [PDF]

				H. Kawanishi, Y. Matsui, M. Ito, J. Watanabe, T. Takahashi, K. Nishizawa, H. Nishiyama, T. Kamoto, Y. Mikami, Y. Tanaka, et al. Secreted CXCL1 Is a Potential Mediator and Marker of the Tumor Invasion of Bladder Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2579 - 2587. [Abstract] [Full Text] [PDF]

				M. Hsu, S.-Y. Wu, S.-S. Chang, I.-J. Su, C.-H. Tsai, S.-J. Lai, A.-L. Shiau, K. Takada, and Y. Chang Epstein-Barr Virus Lytic Transactivator Zta Enhances Chemotactic Activity through Induction of Interleukin-8 in Nasopharyngeal Carcinoma Cells J. Virol., April 1, 2008; 82(7): 3679 - 3688. [Abstract] [Full Text] [PDF]

				C. R. Amura, K. S. Brodsky, B. Gitomer, K. McFann, G. Lazennec, M. T. Nichols, A. Jani, R. W. Schrier, and R. Brian Doctor CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation Am J Physiol Cell Physiol, March 1, 2008; 294(3): C786 - C796. [Abstract] [Full Text] [PDF]

				C. Scheibenbogen, P. Ghadjar, and U. Keilholz In Reply J. Clin. Oncol., November 10, 2006; 24(32): 5174 - 5174. [Full Text] [PDF]